David Gunn, Rabia Topan, Lorna Barnard, Ron Fried, Ivana Holloway, Richard Brindle, Maura Corsetti, Mark Scott, Adam Farmer, Kapil Kapur, David Sanders, Maria Eugenicos, Nigel Trudgill, Peter Whorwell, John Mclaughlin, Ayesha Akbar, Lesley Houghton, Phil G Dinning, Qasim Aziz, Alexander C Ford, Amanda J Farrin, Robin Spiller
BACKGROUND: Ondansetron may be beneficial in irritable bowel syndrome with diarrhoea (IBS-D). AIM: To conduct a 12-week parallel group, randomised, double-blind, placebo-controlled trial of ondansetron 4 mg o.d. (titrated up to 8 mg t.d.s.) in 400 IBS-D patients. PRIMARY ENDPOINT: % responders using the Food and Drug Administration (FDA) composite endpoint. Secondary and mechanistic endpoints included stool consistency (Bristol Stool Form Scale) and whole gut transit time (WGTT)...
March 3, 2023: Alimentary Pharmacology & Therapeutics